Merck Zocor U.S. Sales Headed Past $3 Bil.: Company Sees 20% Growth
U.S. sales of Zocor appear on track to top $3 bil. in 2000 based on projections of 20% growth for the full year.
You may also be interested in...
Searle plans to approach FDA with data from a 13-month trial comparing the ulcer incidence for Celebrex to other nonsteroidal anti-inflammatory drugs, seeking a label change for the COX-2 inhibitor.
Procter & Gamble and marketing partner Aventis will set the price of its Actonel dose for osteoporosis at a discount to Merck's Fosamax.
Douglas Greene, MD, joins Merck Research Laboratories as executive VP-clinical sciences & product development with prior experience serving on FDA's Endocrinologic & Metabolic Drugs Advisory Committee.